PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 6285388

Prophylactic granulocyte transfusions.

C D Buckner·R A Clift·J E Sanders·J A Hersman·B Williams
View original source ↗Export metadata ↓

Abstract

Prophylactic granulocyte transfusions prevent infections in granulocytopenic marrow transplant recipients. In this setting the selection of a single "compatible" related donor for each recipient removes many of the immunologic problems inherent in utilizing multiple random volunteer donors. Graft-versus-host disease is a real risk from granulocyte transfusions and can probably be prevented by irradiation prior to infusion. The problem of cytomegalovirus acquisition through granulocyte and other blood product donors remains to be solved.

Explore related subjects

Anemia, AplasticBacterial InfectionsBlood DonorsBlood TransfusionBone Marrow TransplantationCytomegalovirus InfectionsGraft vs Host DiseaseGranulocytesHumansLeukemiaRiskJournal ArticleResearch Support, U.S. Gov't, P.H.S.

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

C D Buckner, R A Clift, J E Sanders, J A Hersman, B Williams. 1982. Prophylactic granulocyte transfusions.. https://pubmed.ncbi.nlm.nih.gov/6285388/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed1995

Plasma/serum levels of flt3 ligand are low in normal individuals and highly elevated in patients with Fanconi anemia and acquired aplastic anemia.

The flt3 ligand is a growth factor that stimulates the proliferation of hematopoietic progenitor and stem cells. We established a sensitive enzyme-linked immunosorbent assay (ELISA) to measure the concentration of flt3 ligand in plasma or serum from normal individuals, as well as in patients with hematopoietic disorders. Concentrations of flt3 ligand in plasma or serum from normal individuals were quite low: only 12% (7 of 60) of normal individuals had flt3 ligand levels above 100 pg/mL (the limit of detection). In contrast, 86% (19 of 22) of samples from patients with Fanconi anemia and 100% (eight of eight) of samples from patients with acquired aplastic anemia had plasma or serum levels above 100 pg/mL. Mean plasma or serum concentrations (calculated by assigning a value of 0 pg/mL to any sample reading below the level of detection) were as follows: normal volunteers, 14 pg/mL; patients with Fanconi anemia, 1,331 pg/mL; and patients with acquired aplastic anemia, 460 pg/mL. Concentrations of flt3 ligand in blood are, therefore, specifically elevated to a level that may be physiologically relevant in hematopoietic disorders with a suspected stem cell component. The elevated flt3 ligand concentrations in these individuals may be part of a compensatory hematopoietic response to boost the level of progenitor cells.

Anemia, Aplastic↗